Women with a type of breast cancer referred to as HER-2 positive are typically prescribed the medication Herceptin to lower the risk of cancer recurrence.
A study published today makes clear that Herceptin therapy should begin at the same time as chemotherapy, not after chemotherapy is concluded. In about a quarter of women with breast cancer, a protein called HER-2 is over-produced.
Dr. Edith Perez, a breast cancer researcher at the Mayo Clinic in Jacksonville, Fla., and her colleagues looked at a large group of women taking either chemotherapy alone, chemotherapy first and later Herceptin, or chemotherapy and Herceptin at the same time.
LA Times by Shari Roan, 12/12/09